


THE JANUS RECTAL CANCER TRIAL: A RANDOMIZED PHASE II TRIAL TESTING THE EFFICACY OF TRIPLET VERSUS DOUBLET CHEMOTHERAPY TO ACHIEVE CLINICAL COMPLETE RESPONSE IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER

	Eligibility Criteria (see Section 3.2)	Required Initial Laboratory Values	
٠	Clinical stage II or III rectal adenocarcinoma defined as T4N0,	ANC	$\geq 1500/\text{mm}^3$
	or any T with node positive disease (any T, N+); also T3N0	Platelet count:	$\geq 100,000/\text{mm}^3$
	requiring APR or coloanal anastomosis	Creatinine:	\leq 1.5 x upper limit of
٠	No prior systemic chemotherapy, targeted therapy, or		normal (ULN) OR
	immunotherapy; or radiation therapy administered as treatment	Calc. creatinine	\geq 50 mL/min
	for colorectal cancer within the past 5 years	clearance:	
٠	Not pregnant and not nursing	Total bilirubin:	\leq 1.5 x ULN
٠	Age ≥ 18 years	AST/ALT:	\leq 3 x ULN
٠	ECOG Performance Status 0-1		
٠	No upper rectal tumors (distal margin of tumor > 12 cm from		
	the anal verge)		
٠	No recurrent rectal cancer; prior transanal excision, prior distal		
	sigmoid cancer with a low anastomosis		
٠	No known mismatch repair deficient rectal adenocarcinoma		
	*		

Schema



 Patients with locally advanced rectal cancer: <=12cm, T4N0 OR anyT, N1 OR T3N0 that would require APR or coloanal anastomosis

- ** LCRT = long-course chemoradiation (5 weeks)
- ***mFOLFOX6 = 8 cycles (1 cycle = 2 weeks)
- ****mFOLFIRINOX = 8 cycles (1 cycle = 2 weeks)
- # CAPOX = 5 cycles (1 cycle = 3 weeks)

Treatment is to continue for the full course of LCRT and Arm 1 or Arm 2 chemotherapy unless there is a clinical reason to stop. Following neoadjuvant chemotherapy, patients will either proceed to surgery (TME) or watch & wait (WW). Patients will be followed for 8 years or until death, whichever comes first.

Please refer to the full protocol text for a complete description of the eligibility criteria and treatment plan.

LCRT, chemotherapy (as noted in Arm 1 or Arm 2) and surgery will be conducted at the registering institution.

If the Group credited for enrollment is a non-Alliance Group, then other requirements from the credited Group may apply.

Version Date: 10/21/2022